Summary
Amgen Inc. filed an 8-K on December 9, 2004, detailing several material definitive agreements primarily related to amendments and restatements of its employee benefit and incentive plans. These changes were approved by the Compensation Committee and the Board of Directors on December 6, 2004. Key among these is the merger of the Amgen Salary Savings Plan (acquired through the Tularik acquisition) into the main Retirement and Savings Plan, effective December 31, 2004. This merger includes the transfer of assets and full vesting of Tularik plan participants' account balances as of January 1, 2004, though certain distribution options will be eliminated in March 2005. Furthermore, Amgen updated its Change of Control Plan and Executive Incentive Plan, largely to remove references to an "Executive Committee" and clarify administrative designation of participants. Significant amendments were also made to equity incentive plans, including the 1991 Equity Incentive Plan, the Performance Award Program, and the Director Equity Incentive Program. These updates allow for the issuance of stock and performance units in consideration for future services, and the Director Program now bases Restricted Stock Unit (RSU) valuations on the closing stock price on the grant date. The filing also discloses a restricted stock grant to Dr. Dennis M. Fenton, Executive Vice President, Operations and Corporate Compliance Officer, for 20,000 shares, with a repurchase right that vests over three years.
Key Highlights
- 1Amgen is merging the 401(k) plan from its Tularik acquisition into its primary Retirement and Savings Plan, effective December 31, 2004.
- 2Participants in the acquired Tularik savings plan will have their account balances fully vested as of January 1, 2004.
- 3Amendments to the Change of Control and Executive Incentive Plans streamline participant designation processes.
- 4The 1991 Equity Incentive Plan and related programs have been amended to allow equity awards for future services.
- 5The Director Equity Incentive Program now calculates the value of Restricted Stock Units (RSUs) based on the stock's closing price on the grant date.
- 6Dr. Dennis M. Fenton, EVP, Operations, received a grant of 20,000 restricted shares of Amgen common stock, subject to a three-year vesting schedule for the company's repurchase right.